Chao Family Comprehensive Cancer Center
University of California, Irvine
Orange, CA
Accepting patients
MajesTEC-9
Phase 3 Clinical Trial Comparing a Study Medication Alone Versus Pomalidomide, Bortezomib, Dexamethasone or Carfilzomib and Dexamethasone in Patients with Relapsed or Refractory Multiple Myeloma
- Bispecific Antibody
- BCMA
- Randomization
- Phase 3
Not currently accepting
Iberdomide vs. Observation Post Ide-Cel CAR-T
Randomized Phase 2 Study of Iberdomide Maintenance Therapy Following Idecabtagene Vicleucel CAR-T in Multiple Myeloma Patients
- CELMoD
- Maintenance
- Randomization
- Phase 2
Not yet accepting
MagnetisMM-15
Elranatamab Post Trial Access: An Open-Label, Single-Arm Study For Participants with Multiple Myeloma Continuing From Pfizer-Sponsored Elranatamab Clinical Studies
- Bispecific Antibody
- BCMA
- CD3
- Phase 4
Accepting patients
Sonrotoclax (BGB-11417)
A Phase 1b/2 Study of Sonrotoclax (BGB-11417) as Monotherapy and in Various Combinations With Dexamethasone Plus Carfilzomib, Dexamethasone Plus Daratumumab, and Dexamethasone Plus Pomalidomide in Multiple Myeloma
- BCL-2 Inhibitor
- Phase 1/2
- Has results
Accepting patients
AZD0305
AZD0305 as Monotherapy or in Combination With Anticancer Agents in Participants With Relapsed/Refractory Multiple Myeloma
- Antibody Drug Conjugate (ADC)
- GPRC5D
- Phase 1/2
Accepting patients
Dara-SVD vs. Dara-RVD
A Randomized Phase 2 Study of Daratumumab-Selinexor-Velcade-Dexamethasone (Dara-SVD) for High-Risk Newly Diagnosed Multiple Myeloma
- SINE
- Quadruplet Therapy
- Phase 2